BCM
IDXX icon

BluePath Capital Management’s Idexx Laboratories IDXX Stock Holding History

BluePath Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,054
Closed -$514K – 110
2024
Q2 		$514K Sell
1,054
-90
-8% -$45.2K 0.36% 79
2024
Q1 		$618K Sell
1,144
-53
-4% -$29K 0.47% 45
2023
Q4 		$663K Buy
1,197
+21
+2% +$9.86K 0.56% 35
2023
Q3 		$514K Buy
+1,176
New +$586K 0.47% 37

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BluePath Capital Management's IDXX Position: Q3 2024 in Review

BluePath Capital Management sold out of Idexx Laboratories (IDXX) in Q3 2024, closing a stake of 1,054 shares — an estimated $514K sold.

BluePath Capital Management first reported a position in IDXX in Q3 2023 and held it in 4 quarters. The position peaked at $663K in Q4 2023. 1,116 funds tracked by Wall St. Rank hold IDXX as of Q3 2024.

  • BluePath Capital Management reported no remaining Idexx Laboratories position as of Q3 2024 after selling out during the quarter.
  • BluePath Capital Management sold 1,054 Idexx Laboratories shares in Q3 2024, an estimated $514K.
  • BluePath Capital Management first reported a position in Idexx Laboratories in Q3 2023 and held it in 4 quarters.
  • BluePath Capital Management's Idexx Laboratories position peaked at $663K in Q4 2023.
  • 1,116 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2024.

Based on BluePath Capital Management's 13F filing for Q3 2024, filed 29 Oct 2024.